Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
71 hedge funds and large institutions have $19.8M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 20 closing their positions.
235% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $611K
12% less funds holding
Funds holding: 81 → 71 (-10)
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
52% less capital invested
Capital invested by funds: $40.8M → $19.8M (-$21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$905K |
| 2 |
BlackRock
New York
|
+$396K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$202K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$152K |
| 5 |
SW
SteelPeak Wealth
Woodland Hills,
California
|
+$50.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.3M |
| 2 |
Millennium Management
New York
|
-$2.53M |
| 3 |
Renaissance Technologies
New York
|
-$1.7M |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.24M |
| 5 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
-$574K |
EVFM Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2021, worth a combined $19.8M — down 52% from $40.8M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of EVFM and 11 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 13 added.
The largest buyer was Fuller & Thaler Asset Management, opening a new position worth an estimated $905K. The largest seller was Morgan Stanley, cutting an estimated $3.3M.
- 71 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2021, down from 81 in Q2 2021.
- Funds reported $19.8M of Evofem Biosciences, Inc. Common Stock stock for Q3 2021, down 52% quarter-over-quarter.
- 11 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2021 and 20 closed out, a net change of -9 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2021 was Fuller & Thaler Asset Management, an estimated $905K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2021 was Morgan Stanley, an estimated $3.3M sold.
Based on aggregated 13F filings for Q3 2021.